Radosław Birger

Mr. Radosław Birger


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2024 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
MPMagdalena Peruzynska
Magdalena Peruzynska
Anna NowakAnna Nowak
Anna Nowak
Anna Muzykiewicz-SzymańskaAnna Muzykiewicz-Szymańska
Anna Muzykiewicz-Szymańska
ŁKŁukasz Kucharski
Łukasz Kucharski
JKJoanna Klebeko
Joanna Klebeko
Paula Ossowicz-RupniewskaPaula Ossowicz-Rupniewska
Paula Ossowicz-Rupniewska
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain relief and inflammation management, but there are challenges related to poor solubility and bioavailability. We explored modifications of ibuprofen (IBU) by forming ionic pairs using amino acid alkyl esters to enhance solubility without compromising the ability to inhibit cyclooxygenase (COX)-1 and COX-2). We comprehensively evaluated the pharmacological properties of the IBU derivatives, focusing on antioxidant activity (based on the ability to scavenge DPPH and ABTS), biocompatibility (using human dermal fibroblasts), and COX inhibitory potential. The antioxidant activity assays significantly enhanced DPPH scavenging activity for several IBU derivatives, particularly [l-SerOiPr][IBU], suggesting potential therapeutic benefits. There was enhanced cell viability with select derivatives, indicating possible stimulatory effects on cellular proliferation. Finally, predominant COX-1 inhibition across derivatives was consistent with IBU’s profile. This study provides insights into the pharmacological properties of IBU amino acid derivatives, highlighting their potential as therapeutic agents. Further exploration into structure–activity relationships and in vivo efficacy warranted to advance these derivatives toward clinical applications, offering prospects for novel NSAIDs with enhanced efficacy and reduced side effects.

9 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MPMagdalena Peruzynska
Magdalena Peruzynska
RBRadosław Birger
Radosław Birger
PKPatrycja Kłos
Patrycja Kłos
HKHalina Kwiecień
Halina Kwiecień
Łukasz StrukŁukasz Struk
Łukasz Struk
Marek DrozdzikMarek Drozdzik
Marek Drozdzik
Background: Paclitaxel (PTX), a crucial microtubule-stabilising agent in cancer treatment, is limited by its adverse effects and hydrophobic nature, which necessitate the use of toxic solvents. This study proposes a novel approach combining PTX with new microtubule-destabilising compounds at low, safe doses that are ineffective when used individually. Objective: The aim was to evaluate the therapeutic efficacy of combining PTX with previously described pyridine (S1, S22) and benzofuran derivatives (13b, 14), which have demonstrated promising anticancer properties by inhibiting microtubule polymerisation. Methods: The PrestoBlue assay was used to determine the optimal concentrations of each compound, enabling synergistic interactions with a low dose of PTX in HeLa cervical cancer cells. The combined effects of the compounds and PTX on apoptosis, cell cycle distribution, and mitotic spindle formation were then evaluated. Results: The results showed that compounds 13b (1 µM), 14 (0.1 µM), S1 (2 µM), and S22 (2 µM) enhanced the proapoptotic and antimitotic effects of 1 nM PTX, which was ineffective alone. Notably, live-cell imaging revealed that the concurrent use of S1 and PTX produced effects similar to those of a higher PTX concentration (5 nM). Conclusions: These findings suggest that these compounds enhance the anticancer efficacy of low-dose PTX, potentially paving the way for more effective and safer cancer therapies.

Verified
Journal Article
Open access
PDF file
ECElżbieta Cecerska-Heryć
Elżbieta Cecerska-Heryć
MGMałgorzata Goszka
Małgorzata Goszka
MGMarta Gliźniewicz
Marta Gliźniewicz
BGBartłomiej Grygorcewicz
Bartłomiej Grygorcewicz
NSNatalia Serwin
Natalia Serwin
BDBarbara Dolegowska
Barbara Dolegowska
Platelets are actively involved in tissue injury site regeneration by producing a wide spectrum of platelet-derived growth factors such as PDGF (platelet-derived growth factor), IGF-1 (insulin-like growth factor), TGF-β1 (transforming growth factor β), FGF (fibroblast growth factor), etc. A rotating magnetic field (RMF) can regulate biological functions, including reduction or induction regarding inflammatory processes, cell differentiation, and gene expression, to determine the effect of an RMF on the regenerative potential of platelets. The study group consisted of 30 healthy female and male volunteers (n = 15), from which plasma was collected. A portion of the plasma was extracted and treated as an internal control group. Subsequent doses of plasma were exposed to RMF at different frequencies (25 and 50 Hz) for 1 and 3 h. Then, the concentrations of growth factors (IGF-1, PDGF-BB, TGF-β1, and FGF-1) were determined in the obtained material by the ELISA method. There were statistically significant differences in the PDGF-BB, TGF-β1, IGF-1, and FGF-1 concentrations between the analyzed groups. The highest concentration of PDGF-BB was observed in the samples placed in RMF for 1 h at 25 Hz. For TGF-β1, the highest concentrations were obtained in the samples exposed to RMF for 3 h at 25 Hz and 1 h at 50 Hz. The highest concentrations of IGF-1 and FGF-1 were shown in plasma placed in RMF for 3 h at 25 Hz. An RMF may increase the regenerative potential of platelets. It was noted that female platelets may respond more strongly to RMF than male platelets.

1 January 2024 in Mediators of Inflammation
Verified
Journal Article
Open access
ECElżbieta Cecerska-Heryć
Elżbieta Cecerska-Heryć
DNDominika Nieszpór
Dominika Nieszpór
NSNatalia Serwin
Natalia Serwin
EPEwa Pius-Sadowska
Ewa Pius-Sadowska
MGMarta Gliźniewicz
Marta Gliźniewicz
BDBarbara Dolegowska
Barbara Dolegowska
Platelets are the first to reach the site of tissue damage and secrete substances like platelet growth factors (GFs), which perform many different functions in the human body. Many studies suggest that GFs such as transforming GF (TGF), platelet‐derived GF (PDGF), or insulin‐like GF‐1 (IGF‐1) may be markers of survival, disease severity, and post‐coronavirus disease (COVID) complications. The study aimed to analyze the concentration of TGF‐β, IGF‐1, and PDGF‐BB in COVID‐19 patients compared to the control group (GK). The study group consisted of 50 patients (23 men and 27 women) at the time of COVID‐19 detection, 7 days after detection, then 14 and 28 days after detecting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. The GK comprised 48 healthy volunteers (25 women and 23 men). IGF‐1, TGF‐β, and PDGF‐BB concentrations in blood serum by enzyme‐linked immunosorbent assay (ELISA) methods. There was a statistically significant relationship between the concentration of IGF‐1, TGF‐β 1, and PDGF‐BB in the study group (I–IV blood draw) and the GK (p < 0.001). Statistical analysis showed a significant effect on the survival of COVID‐19 patients on IGF‐1 (p = 0.013), TGF‐β (p = 0.013), and PGDF‐BB (p = 0.015) levels. The analysis showed a significant effect of COVID‐19 symptom severity on IGF‐1 levels (p = 0.018), as well as TGF‐β (p = 0.044) and PDGF‐BB (p = 0.047). In the future, GF may serve as a predictor of disease severity and the development of new treatments for COVID‐19. In later studies, the focus should be on finding the relationship of COVID‐19 pathomechanism with all the parameters to understand the processes that occur in the body during SARS‐CoV‐2 virus infection.

1 September 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
ECElżbieta Cecerska-Heryć
Elżbieta Cecerska-Heryć
NSNatalia Serwin
Natalia Serwin
EPEwa Pius-Sadowska
Ewa Pius-Sadowska
KGKlaudia Głowacka
Klaudia Głowacka
APAleksandra Polikowska
Aleksandra Polikowska
BDBarbara Dołęgowska
Barbara Dołęgowska
Introduction: Oxidative stress (OS) occurs when there is an imbalance between reactive oxygen species (ROS) production and the body’s ability to neutralize them. This can lead to cellular damage and is associated with aging and various diseases. Glutathione (GSH) acts as a vital non-enzymatic antioxidant, while enzymes such as glutathione S-transferase (GST) and glutathione reductase (GR) help maintain the body’s redox balance. OS from viruses, including coronavirus, can disrupt inflammation regulation and cause prolonged tissue damage. Aim: This study examines GSH levels and the activities of GST and R-GSSG in the erythrocytes of COVID-19 patients compared to those of healthy controls. Materials and Methods: The study involved 85 COVID-19 patients (42 females and 43 males), with blood samples collected at the time of disease detection and at 7, 14, and 28 days later. The control group included 85 healthy individuals. Antioxidant levels (GSH, GST, R-GSSG) were measured using spectrophotometric methods. Results: COVID-19 patients exhibited a significant decrease in GSH concentration (p < 0.001) and an increase in R-GSSG (p < 0.001) and GST (p = 0.046) activity. Lower GSH levels correlated with a higher risk of death (p = 0.008). Multivariate analysis revealed relationships between GSH and factors such as time since detection, survival rate, hospital stay, and disease severity. Conclusion: COVID-19 disrupts antioxidant enzyme balance, potentially worsening disease severity and increasing mortality risk, especially in older patients.

Verified
Journal Article
Open access
PDF file
ECElżbieta Cecerska-Heryć
Elżbieta Cecerska-Heryć
JMJaśmina Michałów
Jaśmina Michałów
WEWeronika Engwert
Weronika Engwert
JMJulia Marciniak
Julia Marciniak
RBRadosław Birger
Radosław Birger
BDBarbara Dolegowska
Barbara Dolegowska
Diabetes is a common chronic disease. Untreated diabetes may lead to complications such as nephropathy, neuropathy, retinopathy, and macroangiopathies. The main goal in treating diabetes is to limit the development of vascular complications. The FGF (fibroblast growth factor) family, with its potential as a biomarker for diabetic complications, offers a promising avenue for future research and treatment. The study aimed to analyze and compare the concentrations of selected fibroblast growth factors, FGF-2, FGF-19, FGF-22, and FGF-23, in the plasma of patients with type 1 and type 2 diabetes with those of the control group. The study group consisted of 73 patients, including 33 people with type 1 diabetes (18 M and 15 W) aged 18 to 68 years and 40 with type 2 diabetes (20 M and 20 W) aged 25 to 90. The control group consisted of 41 healthy individuals (23 men and 18 women) aged 21 to 56. The FGF-2, FGF-19, FGF-22, and FGF-23 concentrations were measured using ELISA. The study observed a significant relationship between the levels of FGF19 and FGF22 in the serum of patients with type 1 and type 2 diabetes, as well as in the control group (p < 0.001; p < 0.001). Statistical analysis revealed a significant relationship between FGF-2 and FGF-22 concentrations and hypertension (p = 0.03; p = 0.01). A statistically significant difference was also found between the concentrations of FGF-19 and FGF-22 (p = 0.001; p < 0.001) in the serum of people with normal weight and people with overweight and obesity. A significant correlation was also observed between the concentrations of FGF-22 and FGF-23 and arthritis (p = 0.01; p = 0.02). FGF-2, FGF-19, FGF-22, and FGF-23 likely significantly impact diabetes and its complications. In the future, they could serve as biomarkers for diabetic complications, aiding in diagnosis, patient monitoring, and even predicting potential complications for individuals. However, more research in this area is necessary.